External validation of nomograms for predicting lymph node invasion (LNI) in prostate cancer patients with negative PSMA PET-CT. What did we find? The Briganti 2023 nomogram is the most accurate! 📊✅ 🔍 Why does it matter? Extended pelvic lymph node dissection (ePLND) is the

Smarter staging in prostate cancer? 🙋🏼‍♂️🙋🏻‍♂️🙋🏾‍♂️In patients with intermediate/high-risk prostate cancer and negative PSMA PET (miN0), extended pelvic lymph node dissection (ePLND) remains a clinical dilemma. 🔍 This multi-institutional study (n = 282) externally validated five

Performance of PSMA PET/CT on initial diagnosis of prostate cancer: - significantly better than CT + Bone scan - still has false negatives (do ePLND on miN0?) - need more data on how to treat cN0 miN1 patients @JuddMoul #AUA23

💫🌟🔍 Risk calculators transforming surgical decision-making in #ProstateCancer🌟💫 A 20-year analysis (7,371 pts) from a high-volume center shows that implementing Briganti-based nomograms sharply reduced ePLND rates without losing accuracy in detecting pN1 disease — and with

Alvin Goh - hotspots to avoid during cystectomy EPLND

PSMA has 80-90% NPV but poor sensitivity for pelvic lymph nodes - cannot replace staging extended PLND. Plus new data that ePLND reduces distant metastases -Jochen Walz #apccc24

Surgery (with ePLND) may be enough in pN1 prostate cancer @SBoorjian #AUA23

The pleasure of immediate post op urine color for a retzius spare RALP with bilateral EPLND :) Nothing beats continence and outcomes when bladder hangs on the top! Now just waiting for it to turn red after Enoxaparin :(

@joanfundi Fig. 1 – PLND templates: (A) PLND recommended for bladder and prostate cancer inclusive of the obturator fossa, external iliac, and internal iliac nodes. This is referred to as standard PLND for bladder cancer and extended PLND by EAU guidelines for prostate cancer. (B) An ePLND

#EAU2024 ePLND reduces distant metastases but no effect on BCR

PSMA-PET/CT for staging 🇮🇹high risk PCa patients patients (n=207) 🚩N1: 17%; M1a-c: 14% 🚩Major tx change: 11% (RP: 149 to 131, XRT: 17 to 14) 🚩Minor tx change: 2% 🚩20/29 miM1 patients underwent RP + ePLND--> 80% BCR-free post-RP. @urotoday #EAU23

Retrospective study of 👥 542 RARP ± ePLND performed by 6 surgeons using #DaVinci or #HUGORAS robots. 🧐 the association between robotic systems and surgical outcomes. 🤖 378 (70%) #DaVinci 🦾 164 (30%) #HUGORAS Baseline characteristics did not differ between the groups 👇🏻

🚨 NEW #PlatinumOpinion in European Urology by M. J. Roberts, @GGandaglia et al : 💡 Is extended pelvic lymph node dissection (ePLND) still justified in prostate cancer? 📉 No oncologic benefit in RCTs ⚠️ Up to 20% complication rate 🧬 PSMA PET reshapes staging 🔄 2024 EAU

Another excellent day with our Higgins visiting professor @SBoorjian! Prostate cancer highlights: do the RALP, do the ePLND, improve patient care, and DON’T always debate with our radiation oncology friends! 😉 So grateful to Dr. Boorjian for offering us his time and expertise!

Localised Ca Prostate - High Risk Acinar Adeno GS 3+4 PSA 23.7 Lap RP + B/L EPLND Post op no major complications Good Uroflow, Mild SUI HPE - All Margins clear @AIIMSNagpur

Generally a fan of #EAU #ESTRO etc guidelines. But curious why focal RT boost of tumor gets “weak” rating and ePLND gets “strong” 🤔 Only one of these has phase 3 RCT evidence of ⬇️ recurrence, ⬆️nodal/distant MFS, w/o toxicity increase. Reconsider for 2025? @ESTRO_RT @Uroweb

Interesting voting results from #apccc24 consensus panel on whether ePLND should still be done with negative PSMA PET for unfavorable intermediate, high and very high risk #ProstateCancer

Honored to discuss @ASCO (pinch hitting for @UroDocAsh ) S1011 trial results demonstrating NO DFS/OS for EPLND @slernerbcmedu1 concludes that SLND is now standard of care for T2-T4N0 patients undergoing RC. >LN counts, >morbidity. Predominantly T2 cohort with 57%NAC!

💫🌟 Highlights from #EAU24 Day 3! 🌟💫 @OncoAlert https://t.co/gryMn9TyRu 🚀 PCa Game Changers: Debate on therapeutic benefits of ePLND vs. limited dissection. Prof. Boormans & Prof. Rassweiler share insights! 🎥 Must-watch webcasts: Dive into the efficacy of prostate